<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04745078</url>
  </required_header>
  <id_info>
    <org_study_id>0104074</org_study_id>
    <nct_id>NCT04745078</nct_id>
  </id_info>
  <brief_title>Carboxytherapy for Periorbital Dark Circles</brief_title>
  <official_title>Evaluation of the Use of Carboxytherapy in Periorbital Dark Circles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexandria University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexandria University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      the study evaluates carboxytherapy for the treatment of periorbital dark circles&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      two different concentrations of carboxytherapy administered to patients are compared&#xD;
      regarding efficacy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Actual">May 15, 2021</completion_date>
  <primary_completion_date type="Actual">April 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of Melanin index</measure>
    <time_frame>6 weeks</time_frame>
    <description>change in melanin index of the dark circles</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement of erythema index</measure>
    <time_frame>6 weeks</time_frame>
    <description>change in erythema index of the dark circles</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Periorbital Disorder</condition>
  <arm_group>
    <arm_group_label>Carboxy30</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>carboxy30</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carboxy60</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>carboxy60</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Caboxy30</intervention_name>
    <description>carboxy30 to periorbital dark halos</description>
    <arm_group_label>Carboxy30</arm_group_label>
    <other_name>Carboxy30</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Caboxy60</intervention_name>
    <description>carboxy60 to periorbital dark halos</description>
    <arm_group_label>Carboxy60</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy individuals with dark circles&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  infections, scarring, pregnancy, allergy, on treatment for the condition.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ossama H Roushdy, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Alexandria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Medicine,Alexandria University</name>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 3, 2021</study_first_submitted>
  <study_first_submitted_qc>February 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Alexandria University</investigator_affiliation>
    <investigator_full_name>Heba Mahmoud</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <keyword>carboxytherapy</keyword>
  <keyword>dark circles</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

